Skip to content
DraconiticResearch
Search Sources API
194,216 studies31 sourcesUpdated 57 min ago
Peer-reviewedCC BY-NC-NDNeurochemical research

SLC16A13 Promotes Malignant Progression in Glioma via Metabolic Reprogramming and Disruption of Monocarboxylate Homeostasis.

  • Shiqiang Yang1
  • Yanwei Liu2
  • Xuhui Hui3
  • Anqiang Yang4
4 affiliations
  1. 1Department of Neurosurgery, First People's Hospital of Yibin, Yibin, Sichuan, China.
  2. 2Department of Neurology, First People's Hospital of Yibin, Yibin, Sichuan, China.
  3. 3Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
  4. 4Department of Neurosurgery, First People's Hospital of Yibin, Yibin, Sichuan, China. [email protected].
Read full textPDFDOICite

Abstract

Gliomas are the most prevalent primary malignant brain tumors with limited therapeutic targets. Aerobic glycolysis, a hallmark of glioma, depends on the SLC16 monocarboxylate transporter family, including established oncogenic members MCT1 and MCT4. SLC16A13, linked to systemic glucose homeostasis and cellular stress adaptation, remains uncharacterized in glioma. Given the critical role of metabolic flexibility in glioma pathophysiology, we hypothesized that SLC16A13 may represent a contributor to glioma metabolic reprogramming and malignant progression. This study systematically investigated SLC16A13 expression and clinical relevance using The Cancer Genome Atlas (TCGA) and a West China Hospital glioma cohort. Stable SLC16A13-knockdown models were established in U251 and U373 cells via lentiviral shRNA delivery. Cell proliferation, colony formation, apoptosis, and migration were assessed by CCK-8, colony formation, flow cytometry, and wound healing assays, respectively. A subcutaneous xenograft model was employed to evaluate tumor growth in vivo. Intracellular and extracellular metabolite concentrations were quantified by ELISA and HPLC. SLC16A13 was significantly upregulated in glioma tissues compared with non-tumor controls, and high expression was tightly correlated with advanced WHO grade, IDH wild-type status, TERT promoter mutation, and shorter overall survival (HR = 1.57, 95% CI: 1.08-2.27) and progression-free survival (HR = 1.66, 95% CI: 1.15-2.41). In vitro, SLC16A13 knockdown in U251 and U373 glioma cells suppressed proliferation, colony formation, and migration while concomitantly promoting apoptosis. In vivo, SLC16A13 silencing significantly attenuated xenograft tumor growth and reduced Ki-67 proliferative index. Mechanistically, SLC16A13 depletion caused intracellular accumulation of lactate (~ 1.9-fold), pyruvate (~ 2.3-fold), and ketone bodies, accompanied by a 32% increase in the lactate-to-pyruvate ratio and a 28% decrease in the β-hydroxybutyrate-to-acetoacetate ratio, changes consistent with altered monocarboxylate handling and perturbed cellular redox balance. These findings establish SLC16A13 as a previously unrecognized promoter of glioma malignant progression and an independent prognostic biomarker. By disrupting metabolic homeostasis, SLC16A13 contributes to tumor maintenance and aggressive behavior, highlighting its potential as a therapeutic target.

Related

  1. Copper homeostasis dysregulation promotes malignant transformation of renal tubular epithelial cells via the ROS/NF-κB/AID signaling axis
    Yun Yuan, Rubin Chen, Bingqing Xu +5
    Translational andrology and urologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. FBXO17 regulates the malignant progression of colorectal cancer via the Wnt/β-catenin pathway
    Enyan Tang, Yijie Xiao, Xiaohong Qian +2
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. From inflammation to carcinogenesis: MiRNA regulates epithelial-mesenchymal transition to facilitate malignant progression of gastric precancerous lesions
    Yibing Tian, Tai Zhang, Bochao Yuan +3
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  4. CYB5R1 drives stemness and malignant progression via STAM2/STAT3 in chemotherapy-enriched triple-negative breast cancer
    Zhongyu Wang, Jia Li, Lin Geng +11
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  5. PTTG1 drives intestinal-type gastric cancer progression via G2/M checkpoint-mediated cell-cycle reprogramming
    Caihong Hu, Lijun Bian, Lin Luo +10
    iSciencePeer-reviewedCC BY-NC-NDFull textOncologyCell PressEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{yang2026slc16a13,
  title = {{SLC16A13 Promotes Malignant Progression in Glioma via Metabolic Reprogramming and Disruption of Monocarboxylate Homeostasis.}},
  author = {Shiqiang Yang and Yanwei Liu and Xuhui Hui and Anqiang Yang},
  journal = {Neurochemical research},
  year = {2026},
  month = oct,
  doi = {10.1007/s11064-026-04905-5},
  url = {https://europepmc.org/article/MED/42925432},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - SLC16A13 Promotes Malignant Progression in Glioma via Metabolic Reprogramming and Disruption of Monocarboxylate Homeostasis.
AU  - Shiqiang Yang
AU  - Yanwei Liu
AU  - Xuhui Hui
AU  - Anqiang Yang
PY  - 2026
DA  - 2026/10/24
JO  - Neurochemical research
DO  - 10.1007/s11064-026-04905-5
UR  - https://europepmc.org/article/MED/42925432
AB  - Gliomas are the most prevalent primary malignant brain tumors with limited therapeutic targets. Aerobic glycolysis, a hallmark of glioma, depends on the SLC16 monocarboxylate transporter family, including established oncogenic members MCT1 and MCT4. SLC16A13, linked to systemic glucose homeostasis and cellular stress adaptation, remains uncharacterized in glioma. Given the critical role of metabolic flexibility in glioma pathophysiology, we hypothesized that SLC16A13 may represent a contributor to glioma metabolic reprogramming and malignant progression. This study systematically investigated SLC16A13 expression and clinical relevance using The Cancer Genome Atlas (TCGA) and a West China Hospital glioma cohort. Stable SLC16A13-knockdown models were established in U251 and U373 cells via lentiviral shRNA delivery. Cell proliferation, colony formation, apoptosis, and migration were assessed by CCK-8, colony formation, flow cytometry, and wound healing assays, respectively. A subcutaneous xenograft model was employed to evaluate tumor growth in vivo. Intracellular and extracellular metabolite concentrations were quantified by ELISA and HPLC. SLC16A13 was significantly upregulated in glioma tissues compared with non-tumor controls, and high expression was tightly correlated with advanced WHO grade, IDH wild-type status, TERT promoter mutation, and shorter overall survival (HR = 1.57, 95% CI: 1.08-2.27) and progression-free survival (HR = 1.66, 95% CI: 1.15-2.41). In vitro, SLC16A13 knockdown in U251 and U373 glioma cells suppressed proliferation, colony formation, and migration while concomitantly promoting apoptosis. In vivo, SLC16A13 silencing significantly attenuated xenograft tumor growth and reduced Ki-67 proliferative index. Mechanistically, SLC16A13 depletion caused intracellular accumulation of lactate (~ 1.9-fold), pyruvate (~ 2.3-fold), and ketone bodies, accompanied by a 32% increase in the lactate-to-pyruvate ratio and a 28% decrease in the β-hydroxybutyrate-to-acetoacetate ratio, changes consistent with altered monocarboxylate handling and perturbed cellular redox balance. These findings establish SLC16A13 as a previously unrecognized promoter of glioma malignant progression and an independent prognostic biomarker. By disrupting metabolic homeostasis, SLC16A13 contributes to tumor maintenance and aggressive behavior, highlighting its potential as a therapeutic target.
SN  - 0364-3190
SN  - 1573-6903
ER  -